EPOPROSTENOL TEVA ® 1.5 MG
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
EPOPROSTENOL AS SODIUM 1.5 MG
Available from:
SALOMON,LEVIN & ELSTEIN LTD
ATC code:
B01AC09
Pharmaceutical form:
POWDER AND SOLVENT FOR SOLUTION FOR INFUSION
Administration route:
I.V
Manufactured by:
TEVA PARENTERAL MEDICINES INC, USA
Therapeutic group:
EPOPROSTENOL
Therapeutic indications:
Epoprostenol Teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond to conventional therapy.
Authorization date:
2009-11-01
